https://scholars.lib.ntu.edu.tw/handle/123456789/585404
Title: | Seroprevalence survey of selective anti-neuronal autoantibodies in patients with first-episode schizophrenia and chronic schizophrenia | Authors: | Chen C.-H. Cheng M.-C. CHIH-MIN LIU CHEN-CHUNG LIU Lin K.-H. HAI-GWO HWU |
Issue Date: | 2017 | Journal Volume: | 190 | Start page/Pages: | 28-31 | Source: | Schizophrenia Research | Abstract: | Autoimmune encephalopathy caused by autoantibodies against neuronal cell-surface proteins in the brain is a newly discovered disease category associated with psychiatric disorders. Correct diagnosis of this condition relies on the detection of specific autoantibodies in the blood or cerebral spinal fluid in addition to the clinical presentations. The study aimed to understand the seroprevalence of selective anti-neuronal autoantibodies in our patients with schizophrenia. First, we screened for six anti-neuronal autoantibodies in an archived blood sample collected from patients with the first-episode schizophrenia. The six autoantibodies including antibodies against N-methyl-D-aspartate (NMDA) receptor, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 1 and 2, γ-butyric acid receptor type B1 (GABARB1), leucine-rich glioma inactivated-1 (LGI1) protein, and contactin-associated protein-like 2 (CASPR2) protein. A total of 78 plasma samples (46 males and 32 females) were investigated; however, no positive case was identified. In this second study, we screened anti-NMDA receptor autoantibodies in a blood sample of 234 patients with chronic schizophrenia (133 females and 101 males) including 48 patients defined as treatment resistance. None of this sample was detected as positive. The negative findings in this study suggest that the seroprevalence of autoantibodies against neuronal surface proteins might be low in patients diagnosed with schizophrenia. ? 2017 Elsevier B.V. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015872331&doi=10.1016%2fj.schres.2017.03.012&partnerID=40&md5=ebff873229fbd9b5dff8d41b140d16ea https://scholars.lib.ntu.edu.tw/handle/123456789/585404 |
ISSN: | 9209964 | DOI: | 10.1016/j.schres.2017.03.012 | SDG/Keyword: | 4 aminobutyric acid receptor; AMPA receptor; AMPA receptor 1; AMPA receptor 2; contactin; contactin associated protein like 2 protein; gamma butyric acid receptor type B1; leucine; leucine rich glioma inactivated 1 protein; n methyl dextro aspartic acid receptor; n methyl dextro aspartic acid receptor antibody; unclassified drug; autoantibody; nerve protein; adult; antibody blood level; Article; controlled study; disease course; disease duration; DSM-IV; DSM-IV-TR; female; first episode schizophrenia; human; immunohistochemistry; informed consent; major clinical study; male; pathogenesis; priority journal; protein blood level; schizophrenia; seroprevalence; acute disease; blood; chronic disease; clinical trial; drug resistance; immunology; middle aged; multicenter study; prevalence; schizophrenia; seroepidemiology; young adult; Acute Disease; Adult; Autoantibodies; Chronic Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Nerve Tissue Proteins; Prevalence; Schizophrenia; Seroepidemiologic Studies; Young Adult [SDGs]SDG3 |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.